Lupus and SARS-CoV-2: What have we learned after the pandemic? DOI Creative Commons
Rachele Francese, Massimo Rittà,

David Lembo

et al.

Lupus, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 17, 2024

After the end of COVID-19 public health emergency, we analysed relationship between Systemic Lupus Erythematosous (SLE) and from virologist's perspective based on recent findings. SLE co-morbidity present unique challenges, as individuals with may be at increased risk for severe illness due to immune system abnormalities ongoing therapies. Effective management both diseases requires careful monitoring, adherence vaccination programs, preventive measures approved patient-tailored This review covers various aspects, including clinical outcome patients infected by SARS-CoV-2, impact this infection onset or flare-ups benefits population. Furthermore, presents most recommendations in rheumatic patients, those SLE, discussing currently available therapeutic options. Finally, explore effective tools SARS-CoV-2 diagnosis autoimmune conditions examine prognostic biomarkers potential implications their oversight. By adopting a comprehensive approach, address these complexities perspective, aiming improve care vulnerable

Language: Английский

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE DOI Creative Commons
Xuan Wang,

Ankit Pahwa,

Mary T. Bausch-Jurken

et al.

Advances in Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

This systematic literature review and pairwise meta-analysis evaluated the comparative effectiveness of mRNA-1273 versus BNT162b2 in patients with at least one underlying medical condition high risk for severe COVID-19. MEDLINE, Embase, Cochrane databases were searched relevant articles from January 1, 2019 to February 9, 2024. Studies reporting data two doses vaccination adults conditions developing COVID-19 according US Centers Disease Control Prevention included. Outcomes interest SARS-CoV-2 infection (overall, symptomatic, severe), hospitalization due COVID-19, death Risk ratios (RRs) calculated random effects models. Subgroup analyses by specific conditions, number vaccinations, age, variant conducted. Heterogeneity between studies was estimated chi-square testing. The certainty evidence assessed using Grading Recommendations, Assessments, Development, Evaluations framework. Sixty-five observational capturing original/ancestral-containing primary series Omicron-containing bivalent original-BA4-5 vaccinations included meta-analysis. associated significantly lower (RR, 0.85 [95% CI, 0.79–0.92]; I2 = 92.5%), symptomatic 0.75 0.65–0.86]; 62.3%), 0.83 0.78–0.89]; 38.0%), 0.88 0.82–0.94]; 38.7%), 0.84 0.76–0.93]; 1.3%) than BNT162b2. Findings generally consistent across subgroups. Evidence low or very because sufficiently powered randomized controlled trials are impractical this heterogeneous population. Meta-analysis 65 showed that a COVID-19-related

Language: Английский

Citations

1
Systemic lupus erythematosus following COVID-19 vaccination. A systematic review of case reports and case series DOI
Nelson Luis Cahuapaza-Gutierrez

Lupus, Journal Year: 2024, Volume and Issue: 33(4), P. 375 - 386

Published: Feb. 5, 2024

Objective Vaccination against SARS-CoV-2 reduced morbidity and mortality rates due to COVID-19 worldwide. However, several adverse effects have been documented of great interest such as Systemic Lupus Erythematosus (SLE). The aim the present study was perform a systematic review case reports series describing development SLE following vaccination. Methods Case report studies were included. Systematic reviews, narratives, letters editor, correspondence, etc. excluded. A selective bibliographic search performed in PubMed, Scopus, EMBASE databases. In addition, Web Science platform consulted. Joanna Brigs Institute (JBI) tool used assess risk bias quality studies. Statistical Package for Social Sciences (SPSS) 23.0 formal analysis descriptive data. Results 12 met eligibility criteria reported total 16 patients. mean age 42.4 ± 18.69 years. slight predominance post-vaccination observed females (females ( n = 9) males 7). higher association found with Pfizer-BioNTech-162b2 vaccine (75%), followed by Sinopharm (12.5%), Moderna (6.25%). AstraZeneca (6.25%) vaccines. Most cases associated first dose (56.25%), second (37.5%) only one third dose. number days elapsed from administration appearance clinical manifestations between 1 30 days. Mainly there involvement musculoskeletal cutaneous system. All patients responded well treatment good evolution no death. Conclusion Cases vaccination are infrequent. monitoring is recommended persons receiving vaccine, mainly those vaccine.

Language: Английский

Citations

6
Comparative Effectiveness of the mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults With Underlying Medical Conditions: A Systematic Literature Review and Pairwise Meta-Analysis Using GRADE DOI
Xuan Wang,

Ankit Pahwa,

Mary T. Bausch-Jurken

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 14, 2024

ABSTRACT Introduction This systematic literature review and pairwise meta-analysis evaluated the comparative effectiveness of mRNA-1273 versus BNT162b in patients with at least one underlying medical condition high risk for severe COVID-19. Methods MEDLINE, Embase, Cochrane databases were searched relevant articles from January 1, 2019 to February 9, 2024. Studies reporting data two doses BNT162b2 vaccination adults conditions developing COVID-19 according US Centers Disease Control Prevention included. Outcomes interest SARS-CoV-2 infection (overall, symptomatic, severe), hospitalization due COVID-19, death Risk ratios (RRs) calculated random effects models. Subgroup analyses by specific conditions, number vaccinations, age, variant conducted. Heterogeneity between studies was estimated chi-square testing. The certainty evidence assessed using Grading Recommendations, Assessments, Development, Evaluations framework. Results Sixty-five observational capturing original/ancestral-containing primary series Omicron-containing bivalent original-BA4-5 vaccinations included meta-analysis. associated significantly lower (RR, 0.85 [95% CI, 0.79–0.92]; I 2 =92.5%), symptomatic 0.75 0.65–0.86]; =62.3%), 0.83 0.78–0.89]; =38.0%), 0.88 0.82–0.94]; =38.7%), 0.84 0.76–0.93]; =1.3%) than BNT162b2. Findings generally consistent across subgroups. Evidence low or very because sufficiently powered randomized controlled trials are impractical this heterogeneous population. Conclusion Meta-analysis 65 showed that a COVID-19-related

Language: Английский

Citations

4
Vaccination updates and special considerations for systemic lupus erythematosus patients DOI
Jammie Law,

Cristina Sorrento,

Amit Saxena

et al.

Current Opinion in Rheumatology, Journal Year: 2023, Volume and Issue: 36(2), P. 148 - 153

Published: Nov. 16, 2023

Purpose of review We the latest guidelines and note special considerations for systemic lupus erythematosus (SLE) patients when approaching vaccination against SARS-CoV-2, influenza, pneumococcus, herpes zoster, potentially respiratory syncytial virus (RSV) vaccine in future. Recent findings SLE have unique infectious risks due to newer treatments nature disease itself. It is important balance benefit additional protective immunity from updated vaccines possible risk activity exacerbations. Summary continuously evaluate safety immunogenicity specifically patients. Additionally, newly approved RSV should be considered this population reduce severe illness.

Language: Английский

Citations

4
Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study DOI Creative Commons
Leonardo Palazzo,

Julius Lindblom,

Emelie Kihlgren Olsson

et al.

Rheumatology International, Journal Year: 2024, Volume and Issue: 44(10), P. 1923 - 1933

Published: Aug. 13, 2024

Abstract Objective To determine the occurrence of breakthrough COVID-19 infections (BIs) in patients with systemic lupus erythematosus (SLE) compared other rheumatic autoimmune diseases (rAIDs), non-rheumatic (nrAIDs), and healthy controls (HCs). Methods The study was based on data from 7035 fully vaccinated respondents to online COVAD questionnaire SLE (N = 852), rAIDs 3098), or nrAIDs 414), HCs 2671). BI defined as infection occurring individuals ≥ 2 doses (or 1 dose J&J) 14 days after vaccination not 6 months since last vaccine dose. Data were analysed using linear logistic regression models. Results A total 91/852 (10.7%) reported at least one BI. frequency BIs comparable that among (277/2671; p 0.847) nrAID (39/414; 0.552) but higher than (235/3098; 0.005). No demographic factors treatments associated ( 0.05 for all). Joint pain more frequent (odds ratio [OR]: 3.38; 95% confidence interval [CI]: 1.89–6.04; < 0.001) (OR: 2.44; CI: 1.04–5.75; 0.041). Patient did report a hospitalisation need advanced treatment disease HCs, respectively. Conclusion conferred similar protection against terms severity by individuals.

Language: Английский

Citations

0
Lupus and SARS-CoV-2: What have we learned after the pandemic? DOI Creative Commons
Rachele Francese, Massimo Rittà,

David Lembo

et al.

Lupus, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 17, 2024

After the end of COVID-19 public health emergency, we analysed relationship between Systemic Lupus Erythematosous (SLE) and from virologist's perspective based on recent findings. SLE co-morbidity present unique challenges, as individuals with may be at increased risk for severe illness due to immune system abnormalities ongoing therapies. Effective management both diseases requires careful monitoring, adherence vaccination programs, preventive measures approved patient-tailored This review covers various aspects, including clinical outcome patients infected by SARS-CoV-2, impact this infection onset or flare-ups benefits population. Furthermore, presents most recommendations in rheumatic patients, those SLE, discussing currently available therapeutic options. Finally, explore effective tools SARS-CoV-2 diagnosis autoimmune conditions examine prognostic biomarkers potential implications their oversight. By adopting a comprehensive approach, address these complexities perspective, aiming improve care vulnerable

Language: Английский

Citations

0